Condition: Sepsis · Septic Shock · Sponsor: Scandinavian Critical Care Trials Group
The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.
This description comes directly from the study's public registry record.
Morten H Møller, MD, Professor, PhD · 4535458685 · morten.hylander.moeller@regionh.dk
Nick Meier, MD · 4535450606 · nick.meier@regionh.dk
Always discuss trial participation with your own doctor first.
| Rigshospitalet | Copenhagen, København Ø, Denmark | Not Yet Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06184659